11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
31 Jul
TORM-A
Mit syn på Torm, og hvorfor jeg mener der er penge at hente som investor.    Der er 95,7 mia. Torm-a..
25
31 Jul
ZEAL
Mange taler om LixiLan og hvor stort det kan blive - inklusiv mig selv!   Men Zealands lidt upræcise..
23
01 Aug
ZEAL
Jeg skrev igår et indlæg om et projekt hos Zealand Pharma som indenfor meget overskuelig fremtid kan..
16
15:15
BAVA
hermed mit bidrag.   Kerrigsdale snakker om at man skal huske at bruge Apple to apple metoden (side ..
15
31 Jul
 
Kan vi ikke få en service meddelelse på hvad der sker med alle de korrreanske spam indlæg der flyder..
15
29 Jul
OMXC20
Delfin har et indlæg om Varoufakis fra Lars Tvede som 10 personer har tomlet op. Læren er at Varoufa..
15
03 Aug
TORM-A
  Et kig på prospektet i Torm       13.4.2.2 Prospective consolidated financial information for the ..
11
01 Aug
EXQ
Jeg opdagede for et par uger siden at inrater.com havde lavet et system hvor man kunne oprette en mo..
11
29 Jul
I:DAX
Alpe påstår ikke som dig at kunne forudsige markedet i detaljer, derimod giver han bud på sandsynlig..
11
03 Aug
VWS
Energiwatch beskriver det ligefrem som at "Suzlon haler vinder ind på Vestas".   Hvad Børsen, Energi..
10

Stagecoach Group PLC : Director/PDMR Shareholding

04/08/2015 15:58:11
Stagecoach Group plc (the "Company") makes the following notification under the Financial Conduct Authority's Disclosure and Transparency Rule 3.1.4. On 4 Au..

Form 8.3 - Royal Dutch Shell plc

04/08/2015 13:50:55
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Form 8.3 - RSA Insurance Group

04/08/2015 10:45:13
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Crédit Agricole SA is adjusting its organisation to oversee its transformations and enhance collective performance
2
CREDIT AGRICOLE SA : Results second quarter and first half of 2015
3
DSM reports Q2 2015 results
4
LECTRA: Lectra's first apparel manufacturing seminar takes an in-depth look at the new rules of the changing fashion marketplace
5
Brad Keselowski Crew Chief Paul Wolfe Wins Second Straight MOOG® 'Problem Solver' Award After Wild Day at Pocono

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
04 August 2015 22:54:42
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150804.2 - EUROWEB4 - 2015-08-04 23:54:42 - 2015-08-04 22:54:42 - 1000 - Website: OKAY